Ruxolitinib Cream for Hand Eczema

Palo Alto (17 mi)

Age: 18+

Sex: Any

Travel: May be covered

Time Reimbursement: Varies

Trial Phase: Phase 2

Waitlist Available

Sponsor: Incyte Corporation

Prior Safety Data

Trial Summary

What is the purpose of this trial?This trial is testing a cream called ruxolitinib for adults with chronic hand eczema that is moderate to severe. The cream works by blocking enzymes that cause inflammation, which may help reduce eczema symptoms. The goal is to see if this treatment is safe and effective for these patients.

Eligibility Criteria

Adults with chronic hand eczema (CHE) for at least 6 months, experiencing moderate to severe symptoms. Participants must have had previous CHE treatments or been advised against them and agree to prevent pregnancy or fathering children during the trial. Those with known CHE triggers that can't be avoided, serious health conditions, abnormal lab values, recent use of excluded treatments, or UV therapy on hands are not eligible.

Inclusion Criteria

I have been diagnosed with chronic hand eczema for at least 6 months.

I have been treated with at least one prescription chemotherapy, or it was not recommended for me.

I have had hand eczema for more than 3 months or at least 2 flares in the past year.

Treatment Details

The study is testing Ruxolitinib cream's effectiveness and safety compared to a placebo (vehicle) in adults with chronic hand eczema. The goal is to see if this cream can reduce the severity of their skin condition.

2Treatment groups

Experimental Treatment

Placebo Group

Group I: RuxolitinibExperimental Treatment1 Intervention

Ruxolitinib cream 1.5% twice daily (BID) for 16 weeks followed by ruxolitinib cream 1.5% BID for an additional 16-week treatment extension period.

Group II: VehiclePlacebo Group1 Intervention

Vehicle cream for 16 weeks followed by crossover to ruxolitinib cream 1.5% BID in a 16-week treatment extension period.